|
|
|
|
|
Legal status
Patent expired
| (51) | INT.CL. | C07K 14/47 | (2006.01) |
| C07K 16/30 | (2006.01) | ||
| A61K 39/395 | (2006.01) | ||
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 2380903 |
| (13) | Kind of document | T |
| (96) | European patent application number | 11002017.9 |
| Date of filing the European patent application | 2005-05-18 | |
| (97) | Date of publication of the European application | 2011-10-26 |
| (45) | Date of publication and mention of the grant of the patent | 2017-04-05 |
| (46) | Date of publication of the claims translation | 2017-07-10 |
| (30) | Number | Date | Country code |
| 102004024617 | 2004-05-18 | DE |
| (72) |
Türeci, Özlem, DE
Sahin, Ugur, DE
Koslowski, Michael, DE
Fritz, Stefan, DE
Geppert, Harald-Gerhard, DE
|
| (73) |
Astellas Pharma Inc.,
5-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo 103-8411,
JP
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Geno produktai, deferencijuoti navikuose, ir jų naudojimas |
| Differential in tumour gene products and use of same |
| Payment date | Validity (years) | Amount | |
| 2024-05-02 | 347.00 EUR |